City

Clinical trials near Nashville, United States

Active studies with a listed research site in Nashville, United States.

39active studies

20recruiting now

16countries represented

56largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 1, Phase 2

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

Obesity, Metabolic SyndromeCondition

Empagliflozin 25 MG, PlaceboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-09-01 · NCT05972564See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 2

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Opioid Use Disorder, Opioid Use Disorder, ModerateCondition

Tirzepatide, PlaceboTreatment

United States9 locations

T. John Winhusen, PhDSponsor

Updated 2026-08-11 · NCT06651177See eligibility →

Recruiting nowPhase 2

Atomoxetine in Melanocortin Obesity Syndrome

Melanocortin Obesity Syndrome, MCOSCondition

Atomoxetine, PlaceboTreatment

United States3 locations

Icahn School of Medicine at Mount SinaiSponsor

Updated 2026-08-07 · NCT06899178See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowNot applicable

A Study to Improve Skeletal Muscle in Veterans With HIV

HIV, ObesityCondition

w-3 fatty acid, L-carnitineTreatment

United States1 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-06-26 · NCT06845046See eligibility →

Recruiting nowPhase 2

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

HIV, AlcoholCondition

Semaglutide (Rybelsus®), PlaceboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-05-26 · NCT07221214See eligibility →

Recruiting nowPhase 1

Metabolic Effects of Angiotensin-(1-7)

Obesity, Insulin ResistanceCondition

Angiotensin-(1-7), SalineTreatment

United States1 locations

Vanderbilt UniversitySponsor

Updated 2026-05-22 · NCT02646475See eligibility →

Recruiting nowPhase 4

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Type2Diabetes, ASCVDCondition

SGLT2 inhibitor, GLP-1 receptor agonistTreatment

United States36 locations

Brigham and Women's HospitalSponsor

Updated 2026-04-13 · NCT05390892See eligibility →

Recruiting nowNot applicable

Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity

Obesity, Childhood, Diet, HealthyCondition

Whole Foods MyPlate GroupTreatment

United States1 locations

Vanderbilt UniversitySponsor

Updated 2026-03-23 · NCT06464497See eligibility →

Recruiting nowPhase 1, Phase 2

Sympathetic Mechanisms in Obesity-Crossover Design

Obesity, HypertensionCondition

Amlodipine, MoxonidineTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-02-27 · NCT05312892See eligibility →

Recruiting nowPhase 1, Phase 2

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Hypothalamic Obesity, Prader-Willi SyndromeCondition

Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)Treatment

United States7 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2025-12-22 · NCT06239116See eligibility →

Recruiting nowEarly Phase 1

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

Type 1 DiabetesCondition

Semaglutide (Rybelsus®), PlaceboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2025-12-18 · NCT06338553See eligibility →

Recruiting nowNot applicable

The ADAPT Trial: Adapting Evidence-Based Obesity Interventions in Community Settings

Childhood ObesityCondition

Competency Based Approaches to Community Health (COACH)Treatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2025-12-11 · NCT06546696See eligibility →

Recruiting nowNot applicable

Gut Microbiota in Metabolic Surgery

Bariatric Surgery Candidate, Cardiovascular DiseasesCondition

Bariatric SurgeryTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2025-11-04 · NCT05000996See eligibility →

Recruiting nowPhase 4

Tirzepatide in PWS, HO and GNSO

Prader-Willi Syndrome, Hypothalamic ObesityCondition

TirzepatideTreatment

United States3 locations

Grace KimSponsor

Updated 2025-09-16 · NCT06901245See eligibility →

Recruiting nowNot applicable

The Dose Trial: Dose Intensity of Behavioral Interventions for Childhood Obesity

Childhood ObesityCondition

Intensive Behavioral Lifestyle ModificationTreatment

United States2 locations

Vanderbilt University Medical CenterSponsor

Updated 2025-09-08 · NCT06654323See eligibility →

Opening soonPhase 2

HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

Type 2 Diabetes Mellitus (T2DM), SarcopeniaCondition

Calcium-HMB Plus Vitamin D3, Matching placeboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-08-28 · NCT07760948See eligibility →

Opening soonNot applicable

Transition to Ambulatory Bariatric Surgery (TABS) Trial

Obesity and Obesity-related Medical Conditions, Bariatric SurgeryCondition

Same Day DischargeTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-08-18 · NCT07011628See eligibility →

Opening soonPhase 1, Phase 2

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD)Condition

Semaglutide (Rybelsus®), PlaceboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-06-11 · NCT07642635See eligibility →

Invitation onlyNot applicable

Physiologic and Functional Adaptations of Insulin Sensitive Tissues

Diabetes, Insulin ResistanceCondition

Endoscopy biopsy, Surgical biopsyTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2025-12-18 · NCT03407833See eligibility →

Active, not recruitingPhase 2

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Obesity, OverweightCondition

RO7204239, RO7204239 Matching PlaceboTreatment

Poland, Spain35 locations

Hoffmann-La RocheSponsor

Updated 2026-08-11 · NCT06965413See eligibility →

Active, not recruitingPhase 3

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Hypothalamic ObesityCondition

Setmelanotide, PlaceboTreatment

Canada, Germany28 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-08-10 · NCT05774756See eligibility →

Active, not recruitingPhase 2, Phase 3

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Severe Obesity, ObesityCondition

Tirzepatide, Standard of Care post-gastric bypassTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-08-04 · NCT06162715See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

ObesityCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

United States46 locations

Novo Nordisk A/SSponsor

Updated 2026-07-24 · NCT07011667See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingNot applicable

Comparison of Body Composition Changes With Weight Loss Interventions

ObesityCondition

GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic)Treatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-07-14 · NCT07115069See eligibility →

Active, not recruitingNot applicable

Study of Changes in Skeletal Muscle After Caloric Restriction

ObesityCondition

Intervention not listedTreatment

United States1 locations

Vanderbilt UniversitySponsor

Updated 2026-07-10 · NCT00993460See eligibility →

Active, not recruitingPhase 2

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Type 2 Diabetes MellitusCondition

RO7795081, SemaglutideTreatment

Hungary, Poland50 locations

Hoffmann-La RocheSponsor

Updated 2026-07-07 · NCT07112872See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingPhase 2

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

AsthmaCondition

Semaglutide Pen Injector 2.4mg weekly, PlaceboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-06-24 · NCT05254314See eligibility →

Active, not recruitingPhase 2

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Type 2 Diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Argentina, Mexico40 locations

Eli Lilly and CompanySponsor

Updated 2026-03-23 · NCT06037252See eligibility →

Active, not recruitingPhase 1

Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity

Insulin Resistance, HealthyCondition

Phentolamine, SalineTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-03-02 · NCT03318094See eligibility →

Active, not recruitingNot applicable

Insulin Detemir in Obesity Management

Diabetes, ObesityCondition

DetemirTreatment

United States1 locations

Vanderbilt UniversitySponsor

Updated 2026-01-23 · NCT01239550See eligibility →

Active, not recruitingNot applicable

Competency Based Approaches for Community Health 2

ObesityCondition

COACH, School Readiness InterventionTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2025-12-02 · NCT04971044See eligibility →

Active, not recruitingNot applicable

The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

ObesityCondition

AGBSTreatment

United States17 locations

Allurion TechnologiesSponsor

Updated 2024-10-26 · NCT05368259See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Nashville, United States

Current studies

Related cities